May 24, 2018 We issued a bullish report on Marinus Pharmaceuticals (NASDAQ: MRNS) on May 4, 2018 at $4.96. There were bullish patterns,

May 24, 2018We issued a bullish report on Marinus Pharmaceuticals (NASDAQ: MRNS) on May 4, 2018 at $4.96. There were bullish patterns, a short squeeze underway and undervaluation.  The stock is up +23% in under 3 weeks.  Full valuation price target is $6.59 so it has a little room left to run.

Click for report: https://www.woprresearch.com/freereports2/mrns20180504.pdf

Artificial Intelligence is a technology that uses machine intelligence and human like thinking ability to process historical and real-time data to make predictions, recommendations, and decisions. AI is not a single technology but a convergence of various technologies, statistical models, algorithms, and approaches. We have spent 18 years developing 11 categories of strategies that dynamically generate predictive research reports when multiple strategies line  up at the same time in the same direction, with no conflicting strategies present.Our founder and CEO has been on CNBC TV, BLOOMBERG TV, BNN TV, and published in PC Artificial Intelligence along with the Wall Street Journal, Dow Jones, CBS MarketWatch, Equities Magazine, SFO Magazine, Technical Analysis of Stocks and Commodities Magazine, Red Herring, MSNBC and has been an approved research analyst for Investor’s Business Daily. Mr. Ronk reached the Top 15 players (out of nearly 600,000 contestants) during CNBC’s Million Dollar Portfolio Challenge.He was just awarded a 10 year GOLD MEDAL for beating all mutual fund managers over the past 10 years.  This was all done USING THE TECHNOLOGY described in this email.